By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CytomX Therapeutics, Inc. 

650 Gateway Boulevard
Suite 125
South San Francisco  California  94080-7014  U.S.A.
Phone: 650-515-4987 Fax: 650-351-0353



Company News
CytomX Announces Fourth Target Selection By Bristol-Myers Squibb (BMY) Under Strategic Oncology Collaboration 12/5/2016 8:26:05 AM
CytomX Announces Third Quarter 2016 Financial Results And Provides Pipeline Update 11/4/2016 9:58:00 AM
CytomX To Announce Third Quarter 2016 Financial Results 10/27/2016 7:37:23 AM
Deal Spree for AbbVie (ABBV) Continues with $500 Million Cancer Tie-Up with Bay Area's CytomX 4/22/2016 6:16:31 AM
CytomX Added to Russell 2000 Index 12/21/2015 11:49:21 AM
CytomX Selects Probody Drug Conjugate Clinical Candidate, CX-2009, Targeting Highly Expressed Tumor Antigen, CD166 12/11/2015 7:10:00 AM
CytomX To Present At Oppenheimer's 26th Annual Healthcare Conference 12/1/2015 8:44:59 AM
CytomX Reports Third Quarter 2015 Financial Results 11/23/2015 8:17:30 AM
CytomX Highlights Data From Multiple Probody Pipeline Programs At Investor Event During AACR-National Cancer Institute-EORTC Conference 11/9/2015 7:05:50 AM
CytomX And MD Anderson Cancer Center Enter Into Strategic Collaboration For Probody-Enabled CAR-NK Cell Therapies 11/6/2015 6:11:36 AM